Allied Market Research

Global Norfloxacin Market - Opportunities and Industry Forecasts, 2017-2023

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.


Portland, OR -- (SBWIRE) -- 09/18/2017 -- Norfloxacin is a synthetic broad spectrum antibiotic, which acts against most gram-negative and gram-positive bacteria. This antibiotic is mainly used to treat urinary tract infections by inhibiting bacterial cell division.

Access to the full summary:

The major factors that contribute to the growth of the norfloxacin market include the high prevalence of urinary tract infections (UTI), chronic diseases, and rise in geriatric population contributing to a large patient pool. Moreover, large number of clinical trials and innovative R&D approaches to develop advanced antibiotics drive the market growth. However, development of drug-resistant strains and side effects associated with the use of antibiotic restrain the market growth. The development of prospect molecules and novel combination therapies by R&D processes, which are used to treat antibiotic-resistant microbial infections further provides various opportunities for market growth.

The key players operating in this market include Janssen Pharmaceuticals, Merck KGaA, Eli. Lilly & Co., Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbZ-Pharma GmbH, F. Hoffmann-La Roche AG, Shandong Xinhua Pharmaceutical, Kyorin Pharmaceutical Co., Ltd., and Lancer Health Care Pvt. Ltd.

Norfloxacin Market Key Segments:

By Brand Names

- Chibroxin
- Noroxin
- Others

By Application

- Uncomplicated Urinary Tract Infections
- Complicated Urinary Tract Infections
- Uncomplicated Urethral and Cervical Gonorrhea
- Prostatitis
- Others

Get sample PDF:

By Region

North America

- U.S.
- Canada
- Mexico


- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe


- Japan
- China
- India
- Australia
- Rest of Asia-Pacific


- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA